Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GoodRx Holdings

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Expert Ratings for GoodRx Holdings

Analysts have provided the following ratings for GoodRx Holdings (NASDAQ:GDRX) within the last quarter:

Baird Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Baird has decided to maintain its Neutral rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $7.00 to $6.00. Shares of GoodRx Holdings are trading up 6.94% over the last 24 hours, at $6.32 per share. A move to $6.00 would account for a 5.06% decline from the…

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Expert Ratings for GoodRx Holdings

Within the last quarter, GoodRx Holdings (NASDAQ:GDRX) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know

Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

What 16 Analyst Ratings Have To Say About GoodRx Holdings

What 16 Analyst Ratings Have To Say About GoodRx Holdings

Analysts have provided the following ratings for GoodRx Holdings (NASDAQ:GDRX) within the last quarter:

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

GoodRx Holdings: Q1 Earnings Insights

GoodRx Holdings: Q1 Earnings Insights

GoodRx Holdings (NASDAQ:GDRX) reported its Q1 earnings results on Monday, May 9, 2022 at 04:07 PM. Here's what investors need to know about the announcement. Earnings GoodRx Holdings beat estimated earnings by 25.0%, reporting an EPS of $0.1 versus an estimate of $0.08.

Where GoodRx Holdings Stands With Analysts

Where GoodRx Holdings Stands With Analysts

Over the past 3 months, 13 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022

Where GoodRx Holdings Stands With Analysts

Analysts have provided the following ratings for GoodRx Holdings (NASDAQ:GDRX) within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Where GoodRx Holdings Stands With Analysts

Over the past 3 months, 7 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Recap: GoodRx Holdings Q4 Earnings

GoodRx Holdings (NASDAQ:GDRX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:07 PM. Here's what investors need to know about the announcement.

1

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play